Viking TherapeuticsVKTX
VKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 46
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
131% more call options, than puts
Call options by funds: $222M | Put options by funds: $96M
58% more repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 100
5.72% less ownership
Funds ownership: 73.59% [Q4 2024] → 67.87% (-5.72%) [Q1 2025]
9% less funds holding
Funds holding: 406 [Q4 2024] → 369 (-37) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 99
44% less capital invested
Capital invested by funds: $3.3B [Q4 2024] → $1.84B (-$1.46B) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
15%
upside
Avg. target
$83
217%
upside
High target
$104
299%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Cantor Fitzgerald Steven Seedhouse | 299%upside $104 | Overweight Initiated | 28 Apr 2025 |
Truist Securities Joon Lee | 188%upside $75 | Buy Reiterated | 28 Apr 2025 |
Morgan Stanley Michael Ulz | 291%upside $102 | Overweight Maintained | 24 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis | 291%upside $102 | Buy Reiterated | 24 Apr 2025 |
Goldman Sachs Richard Law | 15%upside $30 | Neutral Initiated | 8 Apr 2025 |
Financial journalist opinion
Based on 13 articles about VKTX published over the past 30 days
Neutral
Zacks Investment Research
2 days ago
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.59, representing a -1.26% change from its previous close.
Negative
The Motley Fool
1 week ago
1 Stock Down 34% This Year to Buy and Hold
Shares of Viking Therapeutics (VKTX 2.88%), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues.
Positive
Seeking Alpha
1 week ago
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in multiple metabolic diseases, making it an attractive acquisition target. VKTX's VK2735 offers strong weight loss efficacy and dual formulation flexibility, but faces tough competition and lacks clear differentiation, despite financial stability.
Positive
The Motley Fool
1 week ago
Could Viking Therapeutics Become the Next Eli Lilly?
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (LLY 2.28%) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years.
Positive
The Motley Fool
1 week ago
3 Best Growth Stocks to Buy in June
Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date amid President Trump's global trade reset and persistent inflation concerns, the easy gains of prior years have evaporated.
Neutral
Zacks Investment Research
2 weeks ago
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Positive
Zacks Investment Research
2 weeks ago
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Negative
Seeking Alpha
2 weeks ago
Viking Therapeutics: Buy It For The Future And Ignore The Noise
VKTX remains a speculative, high-risk/reward play, with its future hinging on successful Phase III trial results for its obesity drug pipeline. The company's strong cash position and recent manufacturing partnerships support its path toward commercialization, despite expected negative free cash flow through FY2028. VKTX's diversified pipeline, including NAFLD and rare disease prospects, provides some downside protection as it awaits pivotal clinical milestones.
Positive
The Motley Fool
3 weeks ago
Better Weight Loss Stock: Amgen or Viking Therapeutics?
Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two leaders in this area, Eli Lilly and Novo Nordisk. However, several other companies seem to have somewhat promising prospects in this field.
Positive
Seeking Alpha
3 weeks ago
Viking Therapeutics: Weight-Loss Story Remains Intact
Viking Therapeutics remains a promising weight-loss drug biotech due to the enrollment of new promising trials. The weight-loss sector's momentum has faded some, but Eli Lilly and Novo Nordisk have still generated substantial value for shareholders. Viking Therapeutics has upcoming catalysts, including late-July Phase 2 oral data and Phase 3 injectable trial enrollment, potentially driving significant upside in the stock.
Charts implemented using Lightweight Charts™